Divarasib + Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Trial Timeline
Oct 24, 2025 → Oct 31, 2030
NCT ID
NCT06793215About Divarasib + Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin
Divarasib + Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin is a phase 3 stage product being developed by Chugai Pharmaceutical for Non-Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06793215. Target conditions include Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06793215 | Phase 3 | Recruiting |
Competing Products
20 competing products in Non-Small Cell Lung Cancer